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Advanced Therapy Medicinal Products (ATMPs) pose a continuing challenge to manufacturing process 
development. Despite the adoption of a structured approach to development through systematic frameworks 
such as Quality by Design, a costly rate of process failure or underperformance is encountered at key transitions 
such as transfer to contract manufacture organizations or changes of scale or equipment. The complexity of the 
products, particularly the cell culture step, is frequently a contributor to such issues; this complexity challenges 
many process development tools, in particular the number of potential process variables and consequences 
results in a lower quality of evidence base informing early risk assessments, creates difficulties in experimental 
prioritization and efficiency, and can result in poor experimental coherence over the course of product 
development (i.e. a failure to efficiently harness/record all data and apply to manufacturing goals). We have 
proposed that rooting development in a suitable process model would lessen these issues. We have developed 
a framework that takes advantage of the commonality across ATMP manufacturing processes(1). For example, 
features such as cell growth, paracrine inhibition or lineage selection, and cell death are representable by a 
limited set of mathematical building blocks. These behaviors interact with process operation to determine critical 
manufacturing outcomes such as product cost and identity. From an operational perspective there are a limited 
number of common process operations such as dilutions, purification or factor additions. This enables a 
modelling framework that can be constrained whilst still representing a wide range of process dynamic 
hypotheses and associated manufacturing scenarios. Case studies will be presented across a variety of 
platforms. These include intensification of hematopoietic lineage cell processing in suspension bioreactors 
(ambr15) including erythroblast and T-cell processing. In each of these cases a model of cell population growth 
was developed to optimize short term cell volume productivity. This was applied over a longer timeframe to 
quantify risks (on yield and phenotypic selection) of longer term operational strategies and control such as feed 
rates or variability in timings and volumes. This provides a basis to specify manufacture based on cost targets, 
operational constraints (e.g. feed frequency, reactor size) and risk tolerance. We will further present application 
of the same approach to gain insight into optimization of specific culture phenomena, such as lag phase and 
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